Plus Therapeutics, Inc (PSTV)

Etorro trading 970x250
Plus Therapeutics, Inc (PSTV) Logo

About Plus Therapeutics, Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Address: 4200 Marathon Boulevard, Austin, TX, United States, 78756

Plus Therapeutics, Inc News and around…

Latest news about Plus Therapeutics, Inc (PSTV) common stock and company :

Is Plus Therapeutics (NASDAQ:PSTV) A Risky Investment?
22 Nov, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial
18 Nov, 2021 FinancialContent

Plus Therapeutics Inc(NASDAQ: PSTV)released interim datafrom Phase 1 ReSPECT-GBM trial in patients with recurrent ...

Plus Therapeutics Says Its Radiation Technology is The Most Precise in Targeting and Killing Cancer Cells
18 Nov, 2021 FinancialContent

Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between ...

Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
18 Nov, 2021 Yahoo! Finance

Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving absorbed dose greater than 100 Gy is 453.8 days and 330 days, respectively, with seven patients remaining alive AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficul

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
14 Nov, 2021 FinancialContent

Biotech stocks declined for the second straight week amid a broader market pullback, along withearnings news from small- and ...

Plus Therapeutics Announces New Employment Inducement Grants
12 Nov, 2021 Yahoo! Finance

AUSTIN, Texas, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that on November 11, 2021, it granted option awards to Norman LaFrance, M.D. Consistent with the disclosures contained in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on September 13, 2021, the Company agreed to gra

This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
11 Nov, 2021 FinancialContent

Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between ...

Plus Therapeutics Receives FDA Fast Track Designation for 186RNL Targeted Radiotherapeutic for Leptomeningeal Metastases
09 Nov, 2021 Yahoo! Finance

AUSTIN, Texas, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), a rare complication in which the disease spreads to the membr

Plus Therapeutics to Host Key Opinion Leader Roundtable on ReSPECT™-GBM Trial
03 Nov, 2021 Yahoo! Finance

Company Management and Principal Investigators to Discuss Trial Data Webinar Scheduled for Thursday, November 18, 2021 at 4:00 - 5:00 p.m. ET AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it will host a key opinion leader roundtable discussion on the ReSPECT-GBM trial on Thursday, Novembe

3 Penny Stocks Insiders Are Buying
29 Oct, 2021 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Plus Therapeutics Announces Presentation of ReSPECT-GBM Trial Dosimetery Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
27 Oct, 2021 Yahoo! Finance

Data demonstrated Rhenium-186 NanoLiposome (186RNL) provides sustained, localized radiation treatment for over eight days to the tumor with minimal whole brain and body radiation exposure The analysis of 3D drug distribution and tumor response shows image monitoring is a predictive tool to evaluate delivery and treatment effectiveness Compared to sealed source brachytherapy, 186RNL offers minimally invasive, convenient delivery AUSTIN, Texas, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics,

Plus Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
21 Oct, 2021 Yahoo! Finance

Management to host conference call today at 5:00 p.m. ETAUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent business highlights. “In the third quarter, we made meaningful progress executing our strat

The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
21 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends ...

Earnings Scheduled For October 21, 2021
21 Oct, 2021 FinancialContent

Companies Reporting Before The Bell • Tri Pointe Homes (NYSE:TPH) is estimated to report quarterly earnings at $0.89 ...

Plus Therapeutics Announces FDA Clearance of Investigational New Drug Application for 186RNL for the Treatment of Leptomeningeal Metastases
19 Oct, 2021 Yahoo! Finance

Patient accrual for the Phase 1 dose escalation clinical trial of 186RNL (ReSPECT-LM) is expected in the fourth quarter of 2021 AUSTIN, Texas, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for Rh

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct, 2021 FinancialContent

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market ...

Plus Therapeutics to Announce Third Quarter 2021 Financial Results and Host Conference Call on October 21, 2021
14 Oct, 2021 Yahoo! Finance

AUSTIN, Texas, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report third quarter 2021 financial results on Thursday, October 21, 2021, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and prov

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Plus Therapeutics to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting
30 Sep, 2021 FinancialContent
Plus Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
27 Sep, 2021 FinancialContent
Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
23 Sep, 2021 FinancialContent
Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting
23 Sep, 2021 Yahoo! Finance

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data regarding its Rhenium-186 NanoLiposome (186RNL) investigational radiotherapeutic for recurrent glioblastoma (GBM) at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting being held in person October 24-27, 2

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Plus Therapeutics Announces the Appointment of Industry Veteran, Norman LaFrance, M.D., as the Company’s Chief Medical Officer
13 Sep, 2021 FinancialContent
Plus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
08 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Friday's Pre-Market Session
03 Sep, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) shares rose 68.9% to $9.29 during Friday's pre-market session. The ...

65 Biggest Movers From Yesterday
03 Sep, 2021 FinancialContent

Gainers AgileThought, Inc. (NASDAQ: AGIL) shares surged 69.4% to settle at $23.53 on Thursday. AgileThought 13D Filings from ...

12 Health Care Stocks Moving In Thursday's After-Market Session
02 Sep, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) stock moved upwards by 40.0% to $7.7 during Thursday's after-market session. This ...

46 Stocks Moving In Thursday's Mid-Day Session
02 Sep, 2021 FinancialContent

Gainers Sphere 3D Corp. (NASDAQ: ANY) shares surged 36% to $9.02 as traders circulate a tweet from popular Twitter trader Will ...

Why Is Plus Therapeutics Stock Moving Higher On Thursday?
02 Sep, 2021 FinancialContent

Plus Therapeutics Inc(NASDAQ: PSTV) hasentered into an agreementwithRadioMedix Incto produce the ...

Plus Therapeutics, Inc (PSTV) is a NASDAQ Common Stock listed in , ,

970x250